查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1365704

生物模擬市場：按產品、用途、交付模式和最終用戶：2023-2032 年全球機會分析和產業預測

Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 435 Pages | 商品交期: 2-3個工作天內

價格

2022年生物模擬市場規模為25億美元，預計2032年將達106億美元，2023年至2032年年複合成長率為15.8%。

對人類生物學至關重要的生物過程的電腦輔助模擬稱為生物模擬。生物模擬的目的是基於模型預測生物系統的動力學和行為。模擬模型將生物系統的知識轉化為數學方程式。在藥物開發過程的階段，甚​​至在第一個分子被製造出來之前，模擬模型就被用來檢驗任何假設並修改產品以最佳化其功能或提高指定藥物的性能。可以估計作為藥物的功能。仿真模型有望用作定義有效測試協議並確保從測試中獲得的資訊一致的手段。

生物模擬市場-IMG1

新藥的臨床前測試、先導化合物的鑒定和最佳化、標靶的鑒定和檢驗是生物模擬在藥物研發中應用的主要領域。生物模擬是一種「虛擬」藥物測試，旨在透過應用生物學、化學和藥理學原理以及專有演算法來準確預測藥物或疾病在體內的作用。它構成了藥物的支柱。此外，這項工作還包括收集有關藥物交互作用、安全給藥、毒性預測等的重要見解。

推動全球生物模擬市場成長的關鍵要素包括對藥物研發和市場開拓的需求不斷成長、對個體化藥物的需求不斷成長以及生物模擬軟體和設備技術的快速進步。例如，生物模擬領域的全球領導者 Certara 將於 2022 年 6 月發布免疫抗原性(IG)、免疫腫瘤學(IO) 和疫苗模擬器的新版本，以幫助預測藥物效果並開發新型生物製劑。這項研究正在幫助回答治療方法發展中的重要問題。

此外，製藥和生技產業不斷增加研發投資以開發新藥治療方法，以及癌症、糖尿病、阿茲海默症、心血管疾病和腎臟疾病等慢性病患病的不斷上升，正在推動生物模擬技術的需求增加，這是增加對生物模擬技術的需求的主要要素。軟體並推動市場成長。此外，由於降低藥物研發發現和藥物研發成本的需求不斷增加，以及藥物發現和委外研發機構（CRO）和學術研究機構中生物模擬軟體的日益普及，生物模擬市場正在成長，是推動藥物發現和研發的主要要素。生長。

然而，由於缺乏標準化格式、協議和不同模擬平台之間的互通性，以及研究人員和醫療保健專業人員對生物模擬技術的認知和教育有限，生物模擬市場受到阻礙。另一方面，個人化醫療和生物模擬解決方案在兒童藥物開發中的擴大用途和增加利用預計將為未來年度的生物模擬市場提供進一步的成長機會。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響要素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 擴大生物模擬軟體的採用
      • 生物模擬軟體的技術進步
      • 降低藥物研發和開發成本的需求不斷增加
    • 抑制因素
      • 缺乏標準化和互通性
    • 機會
      • 擴大生物模擬應用並增加對個人化醫療的需求
  • COVID-19 市場影響分析

第4章 生物模擬市場：按產品

  • 概述
  • 軟體
  • 服務

第5章 生物模擬市場：依應用

  • 概述
  • 藥物開發
  • 藥物研發
  • 其他

第6章 生物模擬市場：依交付模式

  • 概述
  • 訂閱模式
  • 擁有型號

第7章 生物模擬市場：依最終使用者分類

  • 概述
  • 製藥和生物技術公司
  • CRO（藥物委外研發機構）
  • 學術/研究機構

第8章 生物模擬市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲
    • 拉丁美洲
    • 中東
    • 非洲

第9章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第10章 公司簡介

  • Certara, Inc.
  • Dassault Systemes
  • Simulations Plus, Inc.
  • Genedata AG
  • SimBioSys
  • Physiomics Plc
  • INOSIM Software GmbH
  • VeriSIM Life
  • Schrodinger, Inc.
  • Cadence Design Systems, Inc.
Product Code: A00288

According to a new report published by Allied Market Research, titled, "Biosimulation Market," The biosimulation market was valued at $2.5 billion in 2022, and is estimated to reach $10.6 billion by 2032, growing at a CAGR of 15.8% from 2023 to 2032. The computer-assisted simulation of biological processes that are essential to human biology is known as biosimulation. The goal of biosimulation is to offer model-based predictions of the dynamics and behavior of a biological system. A simulation model translates the knowledge about the biological system into mathematical equations. In the initial stage of the drug development process, one is anticipated to use the simulation model to test any hypothesis and change the product in order to optimize its function or estimate the chances that a given agent is projected to function as a drug, even before the first molecule is produced. The simulation model is anticipated to be used as a vehicle to define an effective test protocol and to check that information obtained from tests is consistent.

Biosimulation Market - IMG1

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of "virtual" drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Product

  • Software
  • Services

By Application

  • Drug Development
  • Drug Discovery
  • Others

By Delivery model

  • Subscription Model
  • Ownership Model

By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organization (CROs)
  • Academic and Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Key Market Players:

    • SimBioSys
    • Physiomics Plc
    • Genedata AG
    • Simulations Plus, Inc.
    • Cadence Design Systems, Inc.
    • Certara, Inc.
    • VeriSIM Life
    • Schrodinger, Inc.
    • Dassault Systemes
    • INOSIM Software GmbH

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in adoption of biosimulation software
      • 3.4.1.2. Technological advancements in biosimulation software
      • 3.4.1.3. Increase in demand to curtail drug discovery and development costs
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of standardization and interoperability
    • 3.4.3. Opportunities
      • 3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Software
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Services
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Drug Development
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drug Discovery
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Subscription Model
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Ownership Model
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Pharmaceutical and Biotechnology Companies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Contract Research Organization (CROs)
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Academic and Research Institutes
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Application
    • 8.2.4. Market size and forecast, by Delivery model
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Product
      • 8.2.6.1.2. Market size and forecast, by Application
      • 8.2.6.1.3. Market size and forecast, by Delivery model
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Product
      • 8.2.6.2.2. Market size and forecast, by Application
      • 8.2.6.2.3. Market size and forecast, by Delivery model
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Product
      • 8.2.6.3.2. Market size and forecast, by Application
      • 8.2.6.3.3. Market size and forecast, by Delivery model
      • 8.2.6.3.4. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Application
    • 8.3.4. Market size and forecast, by Delivery model
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Product
      • 8.3.6.1.2. Market size and forecast, by Application
      • 8.3.6.1.3. Market size and forecast, by Delivery model
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Product
      • 8.3.6.2.2. Market size and forecast, by Application
      • 8.3.6.2.3. Market size and forecast, by Delivery model
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Product
      • 8.3.6.3.2. Market size and forecast, by Application
      • 8.3.6.3.3. Market size and forecast, by Delivery model
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Product
      • 8.3.6.4.2. Market size and forecast, by Application
      • 8.3.6.4.3. Market size and forecast, by Delivery model
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Product
      • 8.3.6.5.2. Market size and forecast, by Application
      • 8.3.6.5.3. Market size and forecast, by Delivery model
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Product
      • 8.3.6.6.2. Market size and forecast, by Application
      • 8.3.6.6.3. Market size and forecast, by Delivery model
      • 8.3.6.6.4. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Application
    • 8.4.4. Market size and forecast, by Delivery model
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Product
      • 8.4.6.1.2. Market size and forecast, by Application
      • 8.4.6.1.3. Market size and forecast, by Delivery model
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Product
      • 8.4.6.2.2. Market size and forecast, by Application
      • 8.4.6.2.3. Market size and forecast, by Delivery model
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Market size and forecast, by Product
      • 8.4.6.3.2. Market size and forecast, by Application
      • 8.4.6.3.3. Market size and forecast, by Delivery model
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.4. India
      • 8.4.6.4.1. Market size and forecast, by Product
      • 8.4.6.4.2. Market size and forecast, by Application
      • 8.4.6.4.3. Market size and forecast, by Delivery model
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Product
      • 8.4.6.5.2. Market size and forecast, by Application
      • 8.4.6.5.3. Market size and forecast, by Delivery model
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Product
      • 8.4.6.6.2. Market size and forecast, by Application
      • 8.4.6.6.3. Market size and forecast, by Delivery model
      • 8.4.6.6.4. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Application
    • 8.5.4. Market size and forecast, by Delivery model
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Latin America
      • 8.5.6.1.1. Market size and forecast, by Product
      • 8.5.6.1.2. Market size and forecast, by Application
      • 8.5.6.1.3. Market size and forecast, by Delivery model
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.2. Middle East
      • 8.5.6.2.1. Market size and forecast, by Product
      • 8.5.6.2.2. Market size and forecast, by Application
      • 8.5.6.2.3. Market size and forecast, by Delivery model
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.3. Africa
      • 8.5.6.3.1. Market size and forecast, by Product
      • 8.5.6.3.2. Market size and forecast, by Application
      • 8.5.6.3.3. Market size and forecast, by Delivery model
      • 8.5.6.3.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Certara, Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.0. Key strategic moves and developments
  • 10.2. Dassault Systemes
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Simulations Plus, Inc.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
    • 10.3.0. Key strategic moves and developments
  • 10.4. Genedata AG
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.0. Key strategic moves and developments
  • 10.5. SimBioSys
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
  • 10.6. Physiomics Plc
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. INOSIM Software GmbH
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. VeriSIM Life
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.0. Key strategic moves and developments
  • 10.9. Schrodinger, Inc.
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.0. Key strategic moves and developments
  • 10.10. Cadence Design Systems, Inc.
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.0. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. BIOSIMULATION MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 05. BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. BIOSIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 09. BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. BIOSIMULATION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. U.S. BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 22. U.S. BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 24. U.S. BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. CANADA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. CANADA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 28. CANADA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. UK BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. UK BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. UK BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 49. UK BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ITALY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. ITALY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 53. ITALY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. REST OF EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. CHINA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. CHINA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. CHINA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 74. CHINA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 78. AUSTRALIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. INDIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 80. INDIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 82. INDIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 96. LATIN AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. LATIN AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. LATIN AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 99. LATIN AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. MIDDLE EAST BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 101. MIDDLE EAST BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. MIDDLE EAST BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 103. MIDDLE EAST BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. AFRICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 105. AFRICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 106. AFRICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
  • TABLE 107. AFRICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. CERTARA, INC.: KEY EXECUTIVES
  • TABLE 109. CERTARA, INC.: COMPANY SNAPSHOT
  • TABLE 110. CERTARA, INC.: SERVICE SEGMENTS
  • TABLE 111. CERTARA, INC.: PRODUCT PORTFOLIO
  • TABLE 112. CERTARA, INC.: KEY STRATERGIES
  • TABLE 113. DASSAULT SYSTEMES: KEY EXECUTIVES
  • TABLE 114. DASSAULT SYSTEMES: COMPANY SNAPSHOT
  • TABLE 115. DASSAULT SYSTEMES: PRODUCT SEGMENTS
  • TABLE 116. DASSAULT SYSTEMES: PRODUCT PORTFOLIO
  • TABLE 117. SIMULATIONS PLUS, INC.: KEY EXECUTIVES
  • TABLE 118. SIMULATIONS PLUS, INC.: COMPANY SNAPSHOT
  • TABLE 119. SIMULATIONS PLUS, INC.: SERVICE SEGMENTS
  • TABLE 120. SIMULATIONS PLUS, INC.: PRODUCT PORTFOLIO
  • TABLE 121. SIMULATIONS PLUS, INC.: KEY STRATERGIES
  • TABLE 122. GENEDATA AG: KEY EXECUTIVES
  • TABLE 123. GENEDATA AG: COMPANY SNAPSHOT
  • TABLE 124. GENEDATA AG: PRODUCT SEGMENTS
  • TABLE 125. GENEDATA AG: PRODUCT PORTFOLIO
  • TABLE 126. GENEDATA AG: KEY STRATERGIES
  • TABLE 127. SIMBIOSYS: KEY EXECUTIVES
  • TABLE 128. SIMBIOSYS: COMPANY SNAPSHOT
  • TABLE 129. SIMBIOSYS: SERVICE SEGMENTS
  • TABLE 130. SIMBIOSYS: PRODUCT PORTFOLIO
  • TABLE 131. PHYSIOMICS PLC: KEY EXECUTIVES
  • TABLE 132. PHYSIOMICS PLC: COMPANY SNAPSHOT
  • TABLE 133. PHYSIOMICS PLC: SERVICE SEGMENTS
  • TABLE 134. PHYSIOMICS PLC: PRODUCT PORTFOLIO
  • TABLE 135. INOSIM SOFTWARE GMBH: KEY EXECUTIVES
  • TABLE 136. INOSIM SOFTWARE GMBH: COMPANY SNAPSHOT
  • TABLE 137. INOSIM SOFTWARE GMBH: SERVICE SEGMENTS
  • TABLE 138. INOSIM SOFTWARE GMBH: PRODUCT PORTFOLIO
  • TABLE 139. VERISIM LIFE: KEY EXECUTIVES
  • TABLE 140. VERISIM LIFE: COMPANY SNAPSHOT
  • TABLE 141. VERISIM LIFE: SERVICE SEGMENTS
  • TABLE 142. VERISIM LIFE: PRODUCT PORTFOLIO
  • TABLE 143. VERISIM LIFE: KEY STRATERGIES
  • TABLE 144. SCHRODINGER, INC.: KEY EXECUTIVES
  • TABLE 145. SCHRODINGER, INC.: COMPANY SNAPSHOT
  • TABLE 146. SCHRODINGER, INC.: SERVICE SEGMENTS
  • TABLE 147. SCHRODINGER, INC.: PRODUCT PORTFOLIO
  • TABLE 148. SCHRODINGER, INC.: KEY STRATERGIES
  • TABLE 149. CADENCE DESIGN SYSTEMS, INC.: KEY EXECUTIVES
  • TABLE 150. CADENCE DESIGN SYSTEMS, INC.: COMPANY SNAPSHOT
  • TABLE 151. CADENCE DESIGN SYSTEMS, INC.: SERVICE SEGMENTS
  • TABLE 152. CADENCE DESIGN SYSTEMS, INC.: PRODUCT PORTFOLIO
  • TABLE 153. CADENCE DESIGN SYSTEMS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. BIOSIMULATION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF BIOSIMULATION MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMULATION MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL BIOSIMULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. BIOSIMULATION MARKET, BY PRODUCT, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. BIOSIMULATION MARKET, BY APPLICATION, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. BIOSIMULATION MARKET, BY END USER, 2022(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. BIOSIMULATION MARKET BY REGION, 2022(%)
  • FIGURE 25. U.S. BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. CANADA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. MEXICO BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. GERMANY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. FRANCE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. UK BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. ITALY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. SPAIN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. REST OF EUROPE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. JAPAN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. CHINA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. INDIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SOUTH KOREA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. LATIN AMERICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. MIDDLE EAST BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AFRICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: BIOSIMULATION MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. CERTARA, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. CERTARA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. CERTARA, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. DASSAULT SYSTEMES: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. DASSAULT SYSTEMES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. DASSAULT SYSTEMES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. SIMULATIONS PLUS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. SIMULATIONS PLUS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. SIMULATIONS PLUS, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. PHYSIOMICS PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. SCHRODINGER, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. SCHRODINGER, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. SCHRODINGER, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. CADENCE DESIGN SYSTEMS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY REGION, 2022 (%)